Team:Trieste/parts/9

From 2012.igem.org

(Difference between revisions)
 
(10 intermediate revisions not shown)
Line 10: Line 10:
                 <div class="box_contenuti">
                 <div class="box_contenuti">
<h2>Description </h2>  
<h2>Description </h2>  
-
</br>
+
<p> LL-37 is a 37-residue, amphipathic, helical human peptide, members of the cathelicidin family of antimicrobial polypeptides (AMPs) that has been shown to exhibit a broad spectrum of antimicrobial activity. </br>
-
<p> LL-37 is a 37-residue, amphipathic, helical peptide found throughout the body and has been shown to exhibit a broad spectrum of antimicrobial activity. </br>
+
-
<center><img src="https://static.igem.org/mediawiki/2012/c/cd/Ll37_structure.png" width="350px"/></br>
+
-
The figure show an electrostatic surface plot and a cartoon representation of LL-37, stressing the amphipathic nature of the peptide. </center> </br>
+
-
</br>
+
-
The antimicrobial peptides (AMPs) are present in all species investigated. They form an important part of innate immunity, protecting the organism from infection by directly killing invading bacteria. Since pathogenic microorganism show an increasing tendency to be immune against common antibiotics, AMPs carry remarkable pharmaceutical promise as next-generation antibiotics. </br>
+
-
</br>
+
-
<center><img src="https://static.igem.org/mediawiki/2012/0/06/Ll_37_mic.png" width="350px"/></br></center>
+
-
</br>
+
-
The electron micrographs below show how a bacterium is affected by LL-37, a human antimicrobial peptide. The bacterium dies if a threshold called 'minimum inhibitory concentration' (MIC) is reached. Even at concentrations below the MIC, the bacterium shows visible damage.</br>
+
</br>
</br>
 +
The antimicrobial peptides (AMPs) form an important part of innate immunity, protecting the organism from infection by directly killing invading bacteria. Since pathogenic microorganism shows an increasing tendency to be immune against common antibiotics, AMPs carry remarkable pharmaceutical promise as next-generation antibiotics. </br>
 +
<br/>
The exact mechanism by which AMPs kill microorganisms is still under debate.</br>
The exact mechanism by which AMPs kill microorganisms is still under debate.</br>
</br>
</br>
-
It has been found to have additional defensive roles such as regulating the inflammatory response and chemo-attracting cells of the adaptive immune system to wound or infection sites, binding and neutralizing LPS, and promoting re-epthelialization and wound closure.
+
 
</br>
</br>
-
</br>
 
-
Ref and figures: Ulrich et al., 2006; Ramanculov et al., 2001
 
</p>
</p>
<h2>Assembly</h2>
<h2>Assembly</h2>
-
 
+
<p>Obtained by synthesis.</p>
-
<p>Obtained by synthesis</p>
+
</br>  
</br>  
<h2>Looking forward</h2>
<h2>Looking forward</h2>
-
</br>
 
<p>At the beginning, our idea was to use the LL 37 cathelicidin as a toxin, to kill the bacteria from inside. Unfortunately this approach was unsuccessfully as the LL 37 does not kill the bacteria.</br>
<p>At the beginning, our idea was to use the LL 37 cathelicidin as a toxin, to kill the bacteria from inside. Unfortunately this approach was unsuccessfully as the LL 37 does not kill the bacteria.</br>
</br>
</br>
Line 40: Line 29:
The rational of this construct is to create a synergic action were the holin creates the pores through  which the LL 37 can reach his target.</br>
The rational of this construct is to create a synergic action were the holin creates the pores through  which the LL 37 can reach his target.</br>
</br>
</br>
-
<center><img src="https://static.igem.org/mediawiki/2012/4/4f/Hollll37.png" width="350px"/></br></center>
+
<center><img src="https://static.igem.org/mediawiki/2012/9/9f/LL_37_webiste_new.png" width="500px"/></br></center>
</p>
</p>
<h3><a href="http://partsregistry.org/Part:BBa_K875009"target="_blank">Link to the Registry</a></h3>
<h3><a href="http://partsregistry.org/Part:BBa_K875009"target="_blank">Link to the Registry</a></h3>
Line 50: Line 39:
             </div> <!-- end box_main -->
             </div> <!-- end box_main -->
             <div id="box_right"> <!-- start box_right -->
             <div id="box_right"> <!-- start box_right -->
-
             <ul id="sub_menu">
+
             <ul id="sub_menu"><strong>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/1">BBa_K875001</a></li>
+
                <li><a href="https://2012.igem.org/Team:Trieste/parts">Overwiev</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/2">BBa_K875002</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/1">BBa_K875001 - Cumate Op</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/3">BBa_K875003</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/2">BBa_K875002 - Lac OP</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/4">BBa_K875004</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/3">BBa_K875003 - CymR</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/5">BBa_K875005</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/4">BBa_K875004 - OmpA scFv</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/6">BBa_K875006</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/5">BBa_K875005 - OmpA SIP</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/7">BBa_K875007</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/6">BBa_K875006 - PelB scFv</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/8">BBa_K875008</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/7">BBa_K875007 - PelB SIP </a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/9">BBa_K875009</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/8">BBa_K875008 - Tse2 Toxin</a></li>
-
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/10">BBa_K875020</a></li>
+
                 <li class="select"><a href="https://2012.igem.org/Team:Trieste/parts/9">BBa_K875009 - LL 37</a></li>
 +
                 <li><a href="https://2012.igem.org/Team:Trieste/parts/10">BBa_K875020 - Glucosidase</a></li>
 +
</strong>
                 </ul>
                 </ul>

Latest revision as of 01:44, 27 September 2012

BBa_K875009

More

Description

LL-37 is a 37-residue, amphipathic, helical human peptide, members of the cathelicidin family of antimicrobial polypeptides (AMPs) that has been shown to exhibit a broad spectrum of antimicrobial activity.

The antimicrobial peptides (AMPs) form an important part of innate immunity, protecting the organism from infection by directly killing invading bacteria. Since pathogenic microorganism shows an increasing tendency to be immune against common antibiotics, AMPs carry remarkable pharmaceutical promise as next-generation antibiotics.

The exact mechanism by which AMPs kill microorganisms is still under debate.


Assembly

Obtained by synthesis.


Looking forward

At the beginning, our idea was to use the LL 37 cathelicidin as a toxin, to kill the bacteria from inside. Unfortunately this approach was unsuccessfully as the LL 37 does not kill the bacteria.

We thought to use the LL 37 in another way, combined with the T4 holin, (BBa_K112000) a small bacteriophage-encoded proteins that accumulate during the period of late-protein synthesis after infection and cause lysis of the host cell at a precise genetically programmed time.

The rational of this construct is to create a synergic action were the holin creates the pores through which the LL 37 can reach his target.


Link to the Registry


Università degli studi di Trieste ICGEB Illy Fondazione Cassa di Risparmio
iGEM 2012 iGEM 2012 iGEM 2012 iGEM 2012 iGEM 2012 iGEM 2012
HTML Hit Counter

Retrieved from "http://2012.igem.org/Team:Trieste/parts/9"